Highlights

• “So, I do think there is an incremental improvement with the renal safety profile using TAF as opposed to tenofovir-based therapies. The main difference is that we have less long-term data with TAF, you have a couple of years but you do not have 20 years. So, like with anything with HIV, time will tell, but I think if you ask the majority of providers, we would all say that in the clinical trials it looks like there is an improvement with less bone loss and less renal side effects.”
  
• “I mean the whole goal of the single-tablet regimen was simplification, and there is clear medical research to show that a single-tablet regimen, taking a pill once a day, improves adherence compared to confusing multi-tablet regimens multi-times a day, separating out the components.
  
• “Oh, well, we were talking about incremental improvements, cobicistat is a big incremental improvement over ritonavir, so it is certainly a step forward compared to ritonavir, but it is still a booster. So, what does that mean? That means that in terms of side effects there are more issues with GI side effects because of the booster, and because it is a booster there are more issues with drug-drug interactions than using a product, whether it is Triumeq or Biktarvy, that does not have a booster agent in the single-tablet regimen.”